ホーム>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Lucanthone

Lucanthone

カタログ番号GC33126

ルカントンは、アプリン エンドヌクレアーゼ 1 (APE-1) のエンドヌクレアーゼ阻害剤です。

Products are for research use only. Not for human use. We do not sell to patients.

Lucanthone 化学構造

Cas No.: 479-50-5

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$70.00
在庫あり
1mg
$47.00
在庫あり
5mg
$115.00
在庫あり
10mg
$184.00
在庫あり
20mg
$278.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Lucanthone is an endonuclease inhibitor of Apurinic endonuclease-1 (APE-1).

Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. To investigate the anticancer activity of Lucanthone, cell viability is measured by MTT assay. Lucanthone reduces cell viability to a similar extent in a panel of seven breast cancer cell lines. In addition, a direct comparison reveals that Lucanthone is significantly more potent than Chloroquine (CQ) at reducing breast cancer cell viability with a mean IC50 of 7.2 μM versus 66 μM for CQ. Measurement of cell viability in two representative cell lines (MDA-MB-231 and BT-20) by ATPlite assay and trypan blue exclusion reveals comparable results[2].

[1]. Chowdhury SM, et al. Graphene nanoribbons as a drug delivery agent for lucanthone mediated therapy of glioblastoma multiforme. Nanomedicine. 2015 Jan;11(1):109-18. [2]. Carew JS, et al. Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011 Feb 25;286(8):6602-13.

レビュー

Review for Lucanthone

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Lucanthone

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.